Close Menu

Margot Schoenborn

Jun 26, 2019

OmniSeq announced today that it has appointed Margot Schoenborn to succeed Mark Gardner as the firm's CEO. Schoenborn joined the firm as senior VP, general counsel and corporate secretary in 2015 and was later appointed chief administrative officer. Prior to OmniSeq, Schoenborn served as deputy general counsel at the Roswell Park Comprehensive Cancer Center. Before that, she served as a special assistant attorney general for New York and as a assistant US attorney for the Eastern District of New York. 

More Like This

Nov 20, 2019

Twist Bioscience: Patrick Finn

Patrick Finn has been promoted from senior VP of commercial operations to chief operating officer of Twist Bioscience, a new position at the company. Prior to joining Twist in 2015, Finn was VP of sales at Enzymatics, and before that, he held various positions at Agilent Technologies, Beckman Coulter, Invitrogen, and GE Healthcare/Amersham International. He holds a PhD in nucleic acid chemistry from the University of Southampton in England and a BSc in chemistry from Heriot-Watt University in Scotland.

Nov 20, 2019

GenapSys: Frank Witney, Rakesh Sachdev, Hamid Moghadam

In connection with its recent funding round, GenapSys has made several appointments to its board of directors. Joining the board are Frank Witney, former CEO of Affymetrix and Dionex; Rakesh Sachdev, former CEO of Sigma Aldrich and Platform Specialty Products; and Hamid Moghadam, CEO and chairman of Prologis.

Nov 20, 2019

BioTeam: Ari Berman, Stan Gloss

Ari Berman has been promoted from VP of consulting to CEO of BioTeam. He replaces company cofounder Stan Gloss, who will become BioTeam's chief marketing officer. Berman holds a PhD in molecular biology from the University of Texas at Austin.

Nov 20, 2019

ATCC: Raymond Stapleton

Raymond Stapleton has been appointed as president and chief operating officer of biological materials resource and standards organization ATCC. Previously, he was senior VP of technical operations at Iovance Biotherapeutics, and before that, he held various roles at Merck. Stapleton holds a PhD in microbial ecology from the University of Tennessee and a bachelor's degree in biology from Mary Washington College in Fredericksburg, Virginia.

Nov 20, 2019

Sophia Genetics: Milton Silva-Craig

Sophia Genetics has named Milton Silva-Craig to its board of directors. Silva-Craig currently serves as CEO of Q-Centrix, a maker of healthcare data management technology. He previously headed the healthcare business unit of TransUnion and was president and CEO of Emageon, a health imaging software company that he helped lead through an initial public offering before that firm was sold to revenue-cycle management technology vendor Health Systems Solutions.

Nov 14, 2019

SEngine Precision Medicine: Astrid Margossian

SEngine Precision Medicine has hired Astrid Margossian as chief medical officer. Margossian, a surgeon, medical oncologist, and cancer researcher with MD and PhD degrees, previously established and served as medical director of Baylor College of Medicine's Breast Center Buenos Aires and Breast Cancer Research Biobank, which focuses on biomarker discovery for breast cancer. 

Nov 14, 2019

Sema4: Joel Sendek

Sema4 has appointed Joel Sendek as chief financial officer.

Sendek brings more than 25 years of financial experience in the pharmaceutical and biotechnology sector, including overseeing successful initial public offerings at his last two companies.

Previously, Sendek was CFO at Spero Therapeutics and Forward Pharma. He spent more than 15 years as an equities research analyst at Stifel Financial and Lazard, worked in corporate development at Progenics Pharmaceuticals, and was an investment banking analyst at Goldman Sachs. He holds a BA in biochemistry from Rice University.

Nov 13, 2019

Danaher: Jessica Mega, Pardis Sabeti

Danaher has appointed Jessica Mega and Pardis Sabeti to its board of directors. Mega has been the chief medical and scientific officer at Verily Life Sciences since October 2015, and was previously a cardiologist and senior investigator at Brigham & Women's. She has also been a faculty member at Harvard Medical School and a senior investigator with the TIMI Study Group. Mega holds degrees from Stanford University, Yale University School of Medicine, and Harvard School of Public Health.

Sabeti has been an investigator at Howard Hughes Medical Institute since November 2015, and is also a professor at the Center for Systems Biology and the Department of Organismic and Evolutionary Biology at Harvard University. She also teaches in the Department of Immunology and Infectious Diseases at the Harvard School of Public Health. Sabeti holds degrees from the Massachusetts Institute of Technology, University of Oxford, and Harvard Medical School. 

Nov 13, 2019

Human Longevity: Thomas Caskey

Human Longevity has appointed Thomas Caskey as chief medical officer. Caskey is a professor of molecular and human genetics at the Baylor College of Medicine, and is board-certified in internal medicine, medical genetics, and molecular genetics. He is a member of the National Academy of Sciences, Institute of Medicine, Royal Society of Canada and the Texas Academy of Medicine, Engineering and Science. He is also past president of the American Society of Human Genetics and the Human Genome Organization. 

Nov 13, 2019

Abbott: Robert Ford, Miles White

Abbott announced Miles White will be stepping down as CEO on March 31, 2020 after 21 years in the position, and will be replaced by Robert Ford. Ford has been the president and COO of Abbott since October 2018, and was appointed to the board. Before that, Ford was the executive VP of medical devices at the company, and has been at Abbott since 1996. Miles will remain executive chairman of BD's board. 

Nov 12, 2019

Prescient Medicine Holdings: Tony Grover

Tony Grover has been named the chief commercial officer of Prescient Medicine Holdings where he will build and execute go-to-market strategies. Grover was vice president of business development at Banyan Biomarkers. Prior to that, he held various positions at PhotoThera. His immediate focus at Prescient will be the LifeKit Predict test, an in vitro diagnostic test for identifying patients at risk of opioid addiction. The test received breakthrough device designation in February 2018. Another test, LifeKit Prevent, for the detection of precancerous polyps and early-stage carcinomas, received breakthrough device designation in August 2019. 

Nov 07, 2019

Armonica Technologies: Victor Esch

Armonica Technologies, an Albuquerque, New Mexico-based firm developing long-read DNA sequencing technology, has appointed Victor Esch as president and CEO. Esch has more than twenty years of executive and technical experience in the medical device industry, including as CEO of DNA Electronics and CEO of nanoMR, which DNA Electronics acquired in 2015. Esch was a founder of Powervision, which was acquired by Alcon in 2019. He also previously served as chief technology officer for EndoVasix.

Nov 07, 2019

Glympse Bio: Tracey Dawson

Glympse Bio, a firm developing non-invasive disease detection and monitoring technology, has named Tracey Dawson as chief commercial officer and head of strategy. Dawson joins Glympse from Biogen, where she was VP of global product development and commercialization for the multiple sclerosis franchise. Prior to that she was group vice president and head of the US genetic disease franchise for Shire. She has also worked for Genentech and Eli Lilly, and holds a PhD in physical organic chemistry from the University of Hull.

Nov 07, 2019

Epify: Leander Van Neste

Epify, a company developing epigenetic biomarkers for cancer diagnosis, has appointed Leander Van Neste as chief scientific officer. Van Neste joins Epify from miDiagnostics, where he served as vice president of scientific and clinical affairs. He has also served as vice president of clinical and scientific affairs for MDxHealth. Van Neste also simultaneously held academic appointments, including as a professor at Ghent University from 2015 to 2018, and an assistant professor at Universiteit Maastricht from 2013 to 2016. Prior to this he was a visiting research associate at Johns Hopkins School of Medicine.

Nov 05, 2019

Congenica: Heiner Dreismann

Heiner Dreismann has been appointed as a non-executive director and senior independent director of UK genome analysis firm Congenica. Previously, he was president and CEO of Roche Molecular Systems. He was also head of global business development at Roche Diagnostics and a member of Roche's global diagnostics executive committee. Since leaving Roche, he has been on the board of biotechnology and healthcare companies in the US, Europe, and Israel.

NPR reports that the patient who underwent a CRISPR-based treatment for sickle cell disease is doing well.

Resistance to ash dieback disease among some UK ash trees appears polygenic, the Independent reports.

In Nucleic Acids Research this week: sequencing strategy for flash-frozen brain tissue bank samples, new version of ChlamDB, and more.

A UK woman is suing three National Health Service Trusts for not telling her about her father's Huntington's disease diagnosis, the BBC reports.